Menu Search
Equities

Ryvu Therapeutics SA

0RKT:LSE

Ryvu Therapeutics SA

Actions
  • Price (PLN)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Ryvu Therapeutics SA had net income fall 9.94% from a loss of 83.78m to a larger loss of 92.11m despite a 20.32% increase in revenues from 38.95m to 46.86m. An increase in the selling, general and administrative costs as a percentage of sales from 219.24% to 265.46% was a component in the falling net income despite rising revenues.
Gross margin64.77%
Net profit margin-158.15%
Operating margin-175.69%
Return on assets-23.04%
Return on equity-37.68%
Return on investment-28.01%
More ▼

Cash flow in PLNView more

In 2023, cash reserves at Ryvu Therapeutics SA fell by 43.98m. Cash Flow from Financing totalled 240.83m or 513.94% of revenues. In addition the company used 84.55m for operations while cash used for investing totalled 195.54m.
Cash flow per share-3.69
Price/Cash flow per share--
Book value per share8.88
Tangible book value per share8.57
More ▼

Balance sheet in PLNView more

Ryvu Therapeutics SA has a Debt to Total Capital ratio of 29.00%, a higher figure than the previous year's 3.20%.
Current ratio3.32
Quick ratio3.29
Total debt/total equity0.4085
Total debt/total capital0.29
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.